Expected Revenue Growth:
The global molecular biology enzymes and kits & reagents market is projected to reach USD 13.60 Billion by 2022 from USD 6.52 Billion in 2017, at a CAGR of 15.8%.
Growth Boosting Factors:
The key factors driving the growth of this market include increased research activities and R&D investments in the life science industry, rising number of genome projects, technological advancements in the life science industry, and rising incidence of infectious diseases and genetic disorders. However, the privacy concerns related to genetic information and limited reimbursements for genetic testing may hinder the growth of this market to a certain extent.
The molecular biology enzymes and kits & reagents market is well established owing to the dominance by prominent market players. In 2016, Thermo Fisher (US), Merck (Germany), and Illumina (US) held a share of 70% to 75% of the overall market.
Download PDF Brochure@
Thermo Fisher Scientific dominated the molecular biology enzymes and kits & reagents market in 2016. The company provides a wide range of products in this market, including transfection reagents, cloning kits, cloning reagents, PCR enzymes & master mixes, PCR reagents, DNA extraction reagents & kits, and genome editing kits. These products are made available through Thermo Fisher Scientific’s strong sales force and a global network of resellers and distributors. The company has approximately 12,000 sales and service personnel, including highly trained technical specialists. Acquisitions, agreements, and collaborations have also enabled the company to expand its product portfolio and enter emerging markets.
In March 2016, Thermo Fisher Scientific acquired Affymetrix to enhance its antibody product portfolio. In September 2015, the company acquired Alfa Aesar to increase its manufacturing capabilities for research chemicals. Acquisitions; collaboration and agreements; expansion; increasing R&D expenditure; a broad product portfolio; and an extensive distribution and sales network across the globe have enabled Thermo Fishers Scientific to dominate the molecular biology enzymes and kits & reagents market.
Merck designs and manufactures products for academic research markets, applied testing customers, the pharmaceutical & biotechnology industry, and molecular diagnostics laboratories. With the acquisition of Sigma-Aldrich Corporation (US), Merck secured the second-leading position in the global market (with a share of 23.1% in 2016). Sigma-Aldrich was one of the leading developers, manufacturers, and distributors of molecular biology enzymes and kits & reagents. By acquiring Sigma-Aldrich, Merck became a leader in the global life science industry, which valued at more than USD 113 billion (€ 100 billion). The acquisition considerably expanded Merck’s geographic footprint, especially in North America. Merck is present in North America, Europe, APAC, Latin America, and the Middle East & Africa, with ~50,000 employees working at 72 production locations across 66 countries. The firm has 130 global distribution centers.
Some of the other players competing in this market are Illumina (US), QIAGEN (Netherlands), New England Biolabs (US), Promega (US), Agilent (US), Roche (Switzerland), Takara Bio (Japan), Bio Basic (Canada), Jena Bioscience (Germany), and Molecular Biology Resources (US).
Request Sample Pages@
North America to dominate the market in 2017
In 2017, North America is expected to account for the largest share of the molecular biology enzymes and kits & reagents market, followed by Europe, Asia Pacific (APAC), and the Rest of the World (Latin America and the Middle East & Africa). Factors such as increasing research funding for genomics research, rising number of pharmaceutical and biotechnology companies, favorable reimbursement scenario for molecular diagnostics, and growing prevalence of target indications are contributing to the large share of North America.
The molecular biology enzymes and kits & reagents market in several APAC countries, particularly, China, Japan, and India, are expected to witness high growth during the forecast period. This can be attributed to the increasing government interest in biomedical and biotechnology industries, outsourcing of clinical research activities to China, involvement of industry players in the Japanese market, growing pharmaceutical industry in India backed by government initiatives to drive market growth, and initiatives by non-profit organizations.